MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors

Show simple item record

dc.contributor.author Rapoport, Bernardo Leon
dc.contributor.author Anderson, Ronald
dc.contributor.author Cooksley, Tim
dc.contributor.author Johnson, Douglas
dc.date.accessioned 2020-10-26T10:04:18Z
dc.date.issued 2020-09
dc.description.abstract Oncoimmunotherapy with immune checkpoint inhibitor–targeted antibodies has developed as the most significant advance in the management of cancer in recent years. The concept that the immune system was unsuccessful in protecting humans against the development of cancer has changed over the last decade. Checkpoint molecules are inhibitory (PD-1, PDL-1, CTLA-4, TIM-3, LAG-3, BTLA, and HEVM) and stimulatory (CD27, CD40, OX40, GITR, ICOS, and CD137) co-receptors expressed mostly by T cells, but also by other immune cells including antigen-presenting dendritic cells. The basic function of these inhibitory co-receptors is to negatively regulate T cell activation, which is critical in the maintenance of peripheral self-tolerance. The co-inhibitory receptor ligands for these immune checkpoint molecules are, however, also significantly upregulated in various types of cancers, resulting in evasion of anticancer immunity. en_ZA
dc.description.department Immunology en_ZA
dc.description.embargo 2021-09-04
dc.description.librarian hj2020 en_ZA
dc.description.sponsorship The Cancer Association of South Africa (CANSA) and the National Research Foundation (NRF) of South Africa. en_ZA
dc.description.uri http://link.springer.com/journal/520 en_ZA
dc.identifier.citation Rapoport, B.L., Anderson, R., Cooksley, T. et al. MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care in Cancer (2020). https://doi.org/10.1007/s00520-020-05727-z. en_ZA
dc.identifier.issn 0941-4355 (print)
dc.identifier.issn 1433-7339 (online)
dc.identifier.other 10.1007/s00520-020-05727-z
dc.identifier.uri http://hdl.handle.net/2263/76605
dc.language.iso en en_ZA
dc.publisher Springer en_ZA
dc.rights © Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520. en_ZA
dc.subject Oncoimmunotherapy en_ZA
dc.subject Immune checkpoint inhibitor (ICI) en_ZA
dc.subject Cancer en_ZA
dc.title MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record